Lantern Pharma Inc. (LTRN) stock
LTRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.24−0.04 (-13.70%)
Close on Nov 20, 2026Market cap $3.13MP/E –Yield –
Lantern Pharma free cash flow
Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.
Lantern Pharma's free cash flow for the twelve months ending Dec 31, 2025 was -$15.68M. For fiscal 2025 it was -$15.68M. The highest annual figure on record is -$10.61M in fiscal 2021.
Annual free cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$15.68M | – |
| FY2024 | Dec 31, 2024 | -$17.83M | – |
| FY2023 | Dec 31, 2023 | -$14.37M | – |
| FY2022 | Dec 31, 2022 | -$12.80M | – |
| FY2021 | Dec 31, 2021 | -$10.61M | – |
Quarterly free cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | -$2.79M | – |
| Q3 FY2025 | Sep 30, 2025 | -$4.57M | – |
| Q2 FY2025 | Jun 30, 2025 | -$3.94M | – |
| Q1 FY2025 | Mar 31, 2025 | -$4.38M | – |
| Q4 FY2024 | Dec 31, 2024 | -$3.97M | – |
| Q3 FY2024 | Sep 30, 2024 | -$5.59M | – |
| Q2 FY2024 | Jun 30, 2024 | -$5.19M | – |
| Q1 FY2024 | Mar 31, 2024 | -$3.07M | – |
| Q4 FY2023 | Dec 31, 2023 | -$3.39M | – |
| Q3 FY2023 | Sep 30, 2023 | -$3.62M | – |
| Q2 FY2023 | Jun 30, 2023 | -$3.59M | – |
| Q1 FY2023 | Mar 31, 2023 | -$3.77M | – |
| Q4 FY2022 | Dec 31, 2022 | -$2.68M | – |
| Q3 FY2022 | Sep 30, 2022 | -$4.04M | – |
| Q4 FY2021 | Dec 31, 2021 | -$2.04M | – |
| Q3 FY2021 | Sep 30, 2021 | -$4.69M | – |
See a number that looks wrong?